# ADCC OF SMALL CELL CARCINOMA OF THE LUNG

> **NIH NIH R01** · DARTMOUTH COLLEGE · 1988 · $170,206

## Abstract

Although there is much in vitro and in vivo data suggesting that antibody
dependent cell cytotoxicity (ADCC) comprises an effective means of tumor
destruction, the potential role of this mechanism for protection against
human tumors has not been comprehensively explored.  In this application,
we propose to use the reagents and insights we have developed over the past
five years to systematically examine ADCC against Small Cell Carcinoma of
the Lung (SCCL).  We have prepared monoclonal antibodies (MoAb) which are
relatively specific for SCCL cells, have obtained other MoAb reactive with
these tumor cells and have carried out preliminary studies that demonstrate
that SCCL cells are susceptible to killing by ADCC.  We propose to use a
panel of well characterized SCCL lines, and the MoAb reactive with these
cells as the basis for a detailed study of the potential role of ADCC by
human leukocytes in this disease.  In particular, we would develop a system
for analysis of ADCC of SCCL which would involve the use of human
immunoglobulins as mediators of cytotoxicity.  We would compare human
immunoglobulins of different isotypes for their ability to mediate killing
of SCCL cells and explore the effects of antibody specificity, and synergy
of different specificities and/or isotypes.  The ability of leukocyte
subpopulations to kill SCCL cells through different isotypes or through
antibody-independent mechanisms would be characterized and complemented by
analysis of isotype-specific Fc receptor expression.  The modulation of
cellular killing mechanisms by interferons and other factors would be
investigated as well as the effects of mediators on the susceptibility of
SCCL cells to killing.  The importance of SCCL heterogeniety to ADCC or
spontaneous killing of the various forms of this cancer would be
investigated using an extensive panel of SCCL cell lines and patient
cells.  We would investigate the possibility that a specific or general
impairment of cytotoxicity exists in cells from patients with SCCL.
Finally, we would develop a model system using haptens as antigen on SCCL
cells, and anti-hapten monoclonal antibodies to facilitate specific
analysis of the role of antigen density in ADCC and as an alternative
approach to investigating ADCC against SCCL.  These studies would provide
valuable information on this important immune mechanism as it relates to a
significant human tumor and on the potential role of ADCC against human
tumors in general.

## Key facts

- **NIH application ID:** 3170021
- **Project number:** 5R01CA031918-07
- **Recipient organization:** DARTMOUTH COLLEGE
- **SAM.gov UEI:** EB8ASJBCFER9
- **Principal Investigator:** MICHAEL W FANGER
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1988
- **Award amount:** $170,206
- **Award type:** 5
- **Project period:** 1981-07-01 → 1989-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3170021

## Citation

> US National Institutes of Health, RePORTER application 3170021, ADCC OF SMALL CELL CARCINOMA OF THE LUNG (5R01CA031918-07). Retrieved via MORVS 2026-10-25 from https://api.morvs.ai/grant/nih/3170021. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*